Los Angeles,
06:45 AM

Tipsheet: Cedars-Sinai Digestive Disease Experts Share Latest Research at the Scientific Meeting of the American College of Gastroenterology

One Study Honored for Identifying the Risk for Developing Breakthrough Infections Among Certain Inflammatory Bowel Disease Patients Vaccinated Against the Virus That Causes COVID-19

Cedars-Sinai physicians and scientists will share their research findings, aimed at improving treatment for digestive diseases, during the international meeting of the American College of Gastroenterology (ACG). The clinical conference−ACG 2023−will take place Oct. 20-25 in Vancouver, Canada.

Presentations by Cedars-Sinai scientists include a report on the efficacy of a new drug treatment for inflammatory bowel disease (IBD), the impact media coverage has on colorectal screening choices and how virtual reality can be a useful clinical tool for treating functional disorders.

An investigation of the risk some IBD patients may face for breakthrough SARS-CoV-2 infection after vaccination has received a Presidential Poster Award. The ACG gives the award to investigators for “high quality, novel, unique and interesting research.”

Discussions on the use of virtual reality in the treatment of digestive disorders will be offered throughout the conference by Brennan Spiegel, MD, MSHS, who holds the George and Dorothy Gourrich Chair in Digital Health Ethics and is also director of Health Services Research at Cedars-Sinai.

Cedars-Sinai experts are available to comment on a wide variety of clinical and scientific developments in the field of digestive diseases and patient care during the meeting. For interviews, please contact Cedars-Sinai Communications Specialist Laura Coverson by phone, at 310-562-1112, or by email: Laura.Coverson@cshs.org.

ACG 2023 Embargo Policy: All research presented at ACG 2023 is strictly embargoed until 12:00 p.m. PDT on Sunday, Oct, 22, 2023.

Cedars-Sinai Research Highlights at ACG 2023 – All Times PDT

Etrasimod Demonstrated Consistent Efficacy and Safety as a Monotherapy or With Concomitant Use of Corticosteroids and/or 5‑Aminosalicylates: Results From the ELEVATE UC Clinical Program
Poster presented by Andres Yarur, MD, Inflammatory Bowel Disease Center, Cedars-Sinai
Sunday, Oct. 22, 3:30-7 p.m.

ACG Presidential Poster Award
SARS-CoV-2 Breakthrough Infections Are Associated With Corticosteroid Use, Waning Anti-Spike IgG Titers, and Reduced T-Cell Clonal Expansion Among Vaccinated Adults With Inflammatory Bowel Disease
Poster presented by Angela Mujukian, MD, Inflammatory Bowel Disease Center, Cedars-Sinai
Monday, Oct. 23, 10:30 a.m.- 4:15 p.m.

Rapid Symptomatic Relief Is Correlated With Early Endoscopic Response to the Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat Containing X1 (Nlrx1) Agonist Nx-13 in Ulcerative Colitis in a Phase Ib Study
Poster presented by Andres Yarur, MD, Inflammatory Bowel Disease Center, Cedars-Sinai
Tuesday, Oct. 24, 10:30 a.m.- 4 p.m.

Assessing the Impact of Mainstream Media Misinformation on Intent to Undergo Colorectal Cancer (CRC) Screening Among Marginalized Communities: Results From an Online Randomized Controlled Trial (RCT)
Poster presented by Kushagra Mathur, MD, Cedars-Sinai
Tuesday, Oct. 24, 10:30 a.m.- 4:15 p.m.

Did Inaccurate Media Coverage of the NordICC RCT Undermine Perceptions About Colonoscopy for CRC Screening? A Randomized Trial Comparing Screening Intentions After Reading Low- vs. High-Quality Media Reports
Poster presented by Eden Sharabi, MD, MS, Cedars-Sinai
Tuesday, Oct. 24, 10:30 a.m.- 4:15 p.m.